Physician profile
Erin Sinram
NPI 1093093361
$4,121.75
in general payments reported to CMS, 2019-2025
20 companies · $750 in 2025
The $750 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $760 · 2022: $818 · 2023: $725 · 2024: $1,069 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,331.44 | 2021-2025 | |
| Lilly USA, LLC | $621.51 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $463.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.62 | 2021-2025 | Jardiance |
| Pfizer INC. | $241.90 | 2021-2024 | |
| Mylan Specialty L.P. | $238.53 | 2021-2024 | Yupelri, Yupelri |
| Phathom Pharmaceuticals, INC. | $201.86 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $127.04 | 2021-2022 | |
| Amgen INC. | $95.21 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $89.74 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $73.66 | 2023-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $60.97 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.22 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.00 | 2021 | |
| Viatris Specialty LLC | $37.89 | 2025 | Yupelri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.63 | 2025 | Bexsero, Pediarix, Rotarix |
| E.R. Squibb & Sons, L.L.C. | $28.65 | 2022-2025 | Camzyos |
| Vertex Pharmaceuticals Incorporated | $21.28 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $12.86 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Sinram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.